UK Wants ‘Associate Membership’ Of The EMA After Brexit, Prime Minister Says
The UK prime minister Theresa May says that the UK will seek “associate membership” of the European Medicines Agency after Brexit, an announcement that has been welcomed by the UK life sciences industry. However, it remains to be seen what this would entail in terms of UK regulatory input, and whether the EU will agree to negotiating such a status for a departing member state.
You may also be interested in...
The European Council’s draft guidelines on the future UK-EU relationship say that the UK, as a third country outside the EU single market, will not be able to participate in any EU agencies after Brexit, dashing hopes expressed by the government that the UK could have “associate membership” of the EMA. However, the UK BioIndustry Association remains optimistic that some form of regulatory cooperation can be negotiated in the interests of all stakeholders.
A senior German regulator says that changes the EU medicines regulatory network has been making since the UK announced it was leaving the EU means that nothing will ever be the same again irrespective of whether the UK is allowed to remain in network as part of a Brexit deal.
New supply arrangements with the two firms are expected to offer greater protection to people in Europe as the autumn/winter season approaches. The EU’s health crisis preparedness body HERA has also identified its “top three health threats.”